Fusicatenibacter

Overview

Fusicatenibacter is a Gram-positive obligate anaerobic genus within the Lachnospiraceae (Firmicutes). The primary species, F. saccharivorans, was isolated from human feces and is recognized as a beneficial commensal that produces butyrate and modulates intestinal immune responses.

Metal Dependencies

Like other Lachnospiraceae, Fusicatenibacter requires iron for its fermentative enzymes but lacks aggressive iron acquisition systems. This makes it vulnerable to displacement by siderophore-producing Proteobacteria when luminal iron rises during inflammation — a pattern shared with roseburia intestinalis and other butyrate producers.

Ecological Role

F. saccharivorans produces extracellular polysaccharides that suppress pro-inflammatory cytokine production (TNF-alpha, IL-8) by intestinal epithelial cells. This positions it as an active immunomodulator, not merely a passive fermenter. Its butyrate output further supports colonocyte energy metabolism and barrier function. Depletion of Fusicatenibacter may remove a brake on mucosal inflammation.

Conditions Associated

Fusicatenibacter is consistently depleted in inflammatory bowel disease (both Crohn's disease and ulcerative colitis) and colorectal cancer. Its abundance correlates positively with remission in ulcerative colitis patients, making it a potential biomarker for mucosal healing and a candidate for next-generation probiotic development.

Cross-References

References (7)

  1. Li Z, Tao X, Wang D et al. (2024). Alterations of the Gut Microbiota in Patients with Schizophrenia. Frontiers in Psychiatry. doi:10.3389/fpsyt.2024.1366311
  2. Haijing Wang, Yuanjun Wang, Libin Yang et al. (2024). Wang 2024 — Integrated 16S rRNA sequencing and metagenomics insights into microbial dysbiosis and distinct virulence factors in inflammatory bowel disease. Frontiers in Microbiology. doi:10.3389/fmicb.2024.1375804
  3. Xiao-Ce Dai, Yi Yu, Si-Yu Zhou et al. (2024). Assessment of the Causal Relationship between Gut Microbiota and Cardiovascular Diseases: A Bidirectional Mendelian Randomization Analysis. BioData Mining. doi:10.1186/s13040-024-00356-2
  4. Gong W, Jin G, Bao Y et al. (2025). Characteristics and potential diagnostic value of gut microbiota in ovarian tumor patients. Scientific Reports. doi:10.1038/s41598-025-99912-x
  5. Zhu X, Zhang C, Feng S et al. (2024). Zhu et al. 2024 — Intestinal Microbiota Regulates the Gut-Thyroid Axis: The New Dawn of Improving Hashimoto Thyroiditis. Clinical and Experimental Medicine. doi:10.1007/s10238-024-01304-4
  6. Youran Li, Pei Xiao, Rong Cao et al. (2024). Li 2024 — Oral Lyophilized FMT Effects and Microbiota Changes in ASD Children. Frontiers in Pediatrics. doi:10.3389/fped.2024.1369823
  7. Xiao-Ce Dai, Yi Yu, Si-Yu Zhou et al. (2024). Assessment of the causal relationship between gut microbiota and cardiovascular diseases: a bidirectional Mendelian randomization analysis. BioData Mining. doi:10.1186/s13040-024-00356-2